TrovaGene Inc (NASDAQ:TROV) Short Interest Update

TrovaGene Inc (NASDAQ:TROV) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totalling 464,400 shares, a decline of 10.6% from the May 30th total of 519,300 shares. Approximately 11.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 375,900 shares, the days-to-cover ratio is presently 1.2 days.

Shares of TROV stock traded down $0.10 during mid-day trading on Friday, hitting $2.15. The company had a trading volume of 64,672 shares, compared to its average volume of 52,060. TrovaGene has a 52-week low of $2.14 and a 52-week high of $9.65. The company has a 50 day simple moving average of $2.68. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.76 and a quick ratio of 3.76. The stock has a market capitalization of $11.70 million, a P/E ratio of -0.26 and a beta of 0.77.

TrovaGene (NASDAQ:TROV) last released its earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.05. TrovaGene had a negative net margin of 3,540.91% and a negative return on equity of 121.65%. The firm had revenue of $0.16 million for the quarter. As a group, equities analysts expect that TrovaGene will post -4.02 earnings per share for the current year.

TROV has been the topic of several research analyst reports. Noble Financial set a $2.00 target price on shares of Pyxis Tankers and gave the stock a “buy” rating in a report on Friday, May 24th. Maxim Group set a $8.00 target price on shares of TrovaGene and gave the stock a “buy” rating in a report on Thursday, May 23rd. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research downgraded shares of Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a report on Thursday, May 9th.

TrovaGene Company Profile

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Read More: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.